Johnson & Johnson (JNJ)
J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate
J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.
J&J's treatment for depression succeeds in late stage study
Johnson & Johnson said on Wednesday its experimental therapy, seltorexant, met all main and secondary goals in a late-stage study evaluating it in patients with major depressive disorder (MDD) and insomnia symptoms.
J&J acquires rights to skin disorder drug for $1.25 bln
Johnson & Johnson said on Tuesday it had agreed to acquire the rights to an experimental skin disorder treatment from privately held Numab Therapeutics for about $1.25 billion.
Johnson & Johnson (JNJ) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $146.97, denoting a -1.82% change from the preceding trading day.
3 Stocks to Safeguard Your Investments During a Market Meltdown
In today's uncertain market, securing investment returns is essential to protect your wealth from future downturns. Three businesses stand out as islands of stability amid geopolitical unrest and economic uncertainty.
Cancer victims file class action against Johnson & Johnson over ‘fraudulent' bankruptcies
A group of cancer victims sued Johnson & Johnson JNJ.N on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company's bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer.
Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies
A group of cancer victims sued Johnson & Johnson on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company's bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer.
7 Safe-Haven Stocks to Weather Any Storm
Investors often look to safe-haven equities for stability and reliable returns during uncertain economic times. Here are seven strong afe-haven stocks to buy that offer encouraging chances to endure financial disasters.
Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Johnson & Johnson Stock
Johnson & Johnson's dividend currently yields more than 3%. The healthcare giant has increased its payout every year for more than half a century.
J&J-backed startup Rapport files for US IPO
Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson , filed for an initial public offering in the United States on Friday.
J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition
Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.
Johnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
